Urihk Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 30.00 Cr
as on 16-07-2024
- Paid Up Capital ₹ 19.82 Cr
as on 16-07-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -73.25%
(FY 2023)
- Profit -41.83%
(FY 2023)
- Ebitda -47.97%
(FY 2023)
- Net Worth -225.43%
(FY 2023)
- Total Assets -8.90%
(FY 2023)
About Urihk Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 30.00 Cr and a paid-up capital of Rs 19.82 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Urihk Pharmaceutical Private Limited India is Prince Jhanwar as COMPANY SECRETARY. Rajesh Gupta, Tarun Gupta, Xuekui Chen, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51909MH2017FTC302652
- Company No.
302652
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
08 Dec 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Urihk Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prince Jhanwar  | Company Secretary | 02-Dec-2019 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Xuekui Chen  | Director | 13-Apr-2018 | Current |
| Rajesh Sharma | Director | 01-Jan-2020 | Current |
| Rajesh Gupta | Whole-Time Director | 08-Dec-2017 | Current |
Tarun Gupta  | Director | 08-Dec-2017 | Current |
| Xinpei Yu | Director | 13-Apr-2018 | Current |
Financial Performance and Corporate Structure Insights of Urihk Pharmaceutical.
Urihk Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 73.25% decrease. The company also saw a substantial fall in profitability, with a 41.83% decrease in profit. The company's net worth observed a substantial decline by a decrease of 225.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Urihk Pharmaceutical?
In 2023, Urihk Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
P K Pharmatech Private Limited
Active 25 years 4 monthsRajesh Gupta and Tarun Gupta are mutual person
_PRIVATE_LIMITED.webp)
Stg Pharmagenerics Private Limited
Active 7 years 8 monthsRajesh Gupta and Tarun Gupta are mutual person
Joint Force Pharmachem Private Limited
Active 12 years 5 monthsRajesh Gupta and Tarun Gupta are mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Urihk Pharmaceutical?
Urihk Pharmaceutical has a workforce of 79 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Urihk Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Urihk Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
